Search Results - "Kerbouche, Naima"

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: IFM 2020-04 study by Talbot, Alexis, Bobin, Arthur, Tabone, Léa, Lambert, Jérôme, Boccaccio, Catherine, Deal, Cécile, Petillon, Marie-Odile, Allangba, Olivier, Agape, Philippe, Arnautou, Pierre, Belkhir, Rakiba, Cailleres, Sylvie, Chaoui, Driss, Chrétien, Marie-Lorraine, Decaux, Olivier, Schulmann, Samantha, Frenzel, Laurent, Gastaud, Lauris, Huart, Antoine, Hulin, Cyrille, Karlin, Lionel, Laribi, Kamel, Le Calloch, Ronan, Lenain, Pascal, Macro, Margaret, Manier, Salomon, Montes, Lydia, Moreau, Stéphane, Moreau, Philippe, Morel, Véronique, Norwood, James, Piocelle, Frédérique Orsini, Perrot, Aurore, Pica, Gian Matteo, Rey, Philippe, Schmitt, Anna, Stoppa, Anne-Marie, Tiab, Mourad, Touzeau, Cyrille, Vidal, Valérie, Vignon, Marguerite, Vincent, Laure, Van De Wyngaert, Zoé, Zarnitsky, Charles, Kerbouche, Naima, Paka, Prani, Leleu, Xavier, Arnulf, Bertrand, Avet-Loiseau, Hervé

“…Belantamab mafodotin (BM) is an anti-BCMA antibody-drug conjugate (GSK2857916) that represents an alternative option in multiple myeloma. We sought to assess…”
Get full text

Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study by Roussel, Murielle, Texier, Nathalie, Germain, Raphaël, Sapra, Sandhya, Paka, Prani, Kerbouche, Naima, Colin, Xavier, Leleu, Xavier

Get full text

Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study by Roussel, Murielle, Texier, Nathalie, Nael, Virginie, Bitetti, Jacopo, Paka, Prani, Kerbouche, Naima, Sail, Lynda, Colin, Xavier, Leleu, Xavier

“…Objectives The aim of this noninterventional, retrospective ALFA study was to describe belantamab mafodotin effectiveness and safety in patients with…”
Get full text